Title: Mark Chasin - Innovator in Controlled Release Oxycodone Compositions
Introduction
Mark Chasin is an inventor based in Manalapan, NJ (US). He has made significant contributions to the field of pharmaceuticals, particularly in the development of controlled release formulations. Although he currently holds no granted patents, his work has the potential to impact pain management therapies.
Latest Patent Applications
Mark Chasin's latest patent applications include a method for preparing controlled release oxycodone compositions. This method involves creating a solid oral dosage form that comprises up to about 160 mg of oxycodone or a salt thereof. The aim is to control pain in substantially all patients. The process includes forming spheroids with a spheronising agent and oxycodone, followed by coating these spheroids with a controlled-release film coat. The repeated administration of this dosage form every 12 hours results in a mean maximum plasma concentration of oxycodone up to about 240 ng/ml, with a mean minimum plasma concentration of up to about 120 ng/ml.
Conclusion
Mark Chasin's innovative approaches in the pharmaceutical industry highlight his commitment to improving pain management solutions. His work in controlled release formulations demonstrates the potential for significant advancements in patient care.